M5255

Mycophenolic acid

from Penicillium brevicompactum, ≥98% (HPLC), powder, IMP dehydrogenase inhibitor

• Synonym(s): 6-(1,3-Dihydro-7-hydroxy-5-methoxy-4-methyl-1-oxoisobenzofuran-6-yl)-4-methyl-4-hexanoic acid, 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid, NSC 129185
• Empirical Formula (Hill Notation): C₁₇H₂₀O₆
• CAS Number: 24280-93-1
• Molecular Weight: 320.34
• NACRES: NA.77
• PubChem Substance ID: 24896987
• UNSPSC Code: 12352106
• EC Number: 246-119-3
• MDL number: MFCD00036814
• Beilstein/REAXYS Number: 1295848
• Assay: ≥98%

Properties

• Product Name: Mycophenolic acid, ≥98%
• biological source: Penicillium brevicompactum
• Quality Segment: 300
• assay: ≥98%
• color: white to yellow-white
• mp: <143.0 °C
• solubility: methanol: 49.00-51.00 mg/mL, clear, colorless to faintly yellow
• mode of action: enzyme | inhibits
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O
• InChI: 1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
• InChI key: HPNSFSBZBAHARI-RUDMXATFSA-N
• Gene Information: human ... IMPDH1(3614), IMPDH2(3615)

Description

Application

Mycophenolic acid (MPA), produced by Penicillum brevi-compactum, is a selective inhibitor of inosine monphosphate dehydrogenase, thus inhibiting DNA synthesis in T and B lymphocytes. It has also been shown to act as an immunosuppressive agent, and as an inducer of monocyte differentiation and apoptosis in human lymphoid and monocytic cell lines. As a selection agent, MPA is used for transfected animal cells expressing the E. Coli gene for xanthine-guanine phosphoribosyl transferase, and is recommended for use at 25μg/mL.

Biochem/physiol Actions

Mode of Action: This product acts by suppressing the cytokine-induced nitric oxide production, inhibiting early stage biosynthesis of purine nucleotides and as a specific inhibitor of IMP dehydrogenase.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Mycophenolic acid is soluble in methanol at 50 mg/mL, yielding a colorless to faint yellow solution, as well as chloroform, dichloromethane, ethanol and .1 N NaOH. After reconstitution, the recommendation is to sterilize via filtration thorugh a 0.22 μm pore-size filter, aliquot, and freeze at -20°C.

Disclaimer

As supplied, this product should be stored desiccated at 2-8°C, and is stable for 5 years when stored properly.

Safety Information

• Pictograms: GHS08,GHS07,GHS09
• Signal Word: Danger
• Hazard Codes: H302,H341,H360D,H372,H410
• Precautionary Statements: P201 - P202 - P260 - P273 - P301 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Muta. 2 - Repr. 1B - STOT RE 1 Oral
• Target Organs: Immune system
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable
• PPE (personal protective equipment): Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges